AAAAAA
Results:
1-12
|
Results: 12
Authors:
KASINA S
SANDERSON JA
FITZNER JN
SRINIVASAN A
RAO TN
HOBSON LJ
RENO JM
AXWORTHY DB
BEAUMIER PL
FRITZBERG AR
Citation: S. Kasina et al., SIMPLIFIED PREFORMED CHELATE PROTEIN RADIOLABELING WITH TC-99M MERCAPTOACETAMIDOADIPOYLGLYCYLGLYCINE (N3S-ADIPATE), Bioconjugate chemistry, 9(1), 1998, pp. 108-117
Authors:
FRITZBERG AR
Citation: Ar. Fritzberg, ANTIBODY PRETARGETED RADIOTHERAPY - A NEW APPROACH AND A 2ND-CHANCE, The Journal of nuclear medicine, 39(2), 1998, pp. 20
Authors:
CHIANELLI M
SIGNORE A
FRITZBERG AR
MATHER SJ
Citation: M. Chianelli et al., THE DEVELOPMENT OF TC-99M-LABELED INTERLEUKIN-2 - A NEW RADIOPHARMACEUTICAL FOR THE IN-VIVO DETECTION OF MONONUCLEAR CELL INFILTRATES IN IMMUNE-MEDIATED DISEASES, Nuclear medicine and biology, 24(6), 1997, pp. 579-586
Authors:
EHRHARDT GJ
BLUMER ME
SU FM
VANDERHEYDEN JL
FRITZBERG AR
Citation: Gj. Ehrhardt et al., EXPERIENCE WITH ALUMINUM PERRHENATE TARGETS FOR REACTOR PRODUCTION OFHIGH SPECIFIC ACTIVITY RE-186, Applied radiation and isotopes, 48(1), 1997, pp. 1-4
Authors:
KOTTS CE
SU FM
LEDDY C
DODD T
SCATES S
SHALABY MR
WIRTH CM
GILTINAN D
SCHROFF RW
FRITZBERG AR
SHEPARD HM
SLAMON DJ
HUTCHINS BM
Citation: Ce. Kotts et al., (186)RE-LABELED ANTIBODIES TO P185(HER2) AS HER2-TARGETED RADIOIMMUNOPHARMACEUTICAL AGENTS - COMPARISON OF PHYSICAL AND BIOLOGICAL CHARACTERISTICS WITH I-125 AND I-131-LABELED COUNTERPARTS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(2), 1996, pp. 133-144
Authors:
KASINA S
STONE D
FRITZBERG AR
TAIT JF
STRATTON JR
RENO JM
Citation: S. Kasina et al., PREFORMED CHELATE TC-99M RADIOLABELING OF R-ANNEXIN-V FOR ARTERIAL THROMBUS IMAGING, The Journal of nuclear medicine, 37(5), 1996, pp. 106-106
Authors:
ANDERSON CJ
CONNETT JM
GERMAIN CJ
GUO LW
ROGERS BE
SCHWARZ SW
FRITZBERG AR
WELCH MJ
Citation: Cj. Anderson et al., CU-64-LABELED BAT-21T-NR-LU-10 FAB - AN AGENT FOR PET IMAGING AND RADIOIMMUNOTHERAPY, The Journal of nuclear medicine, 37(5), 1996, pp. 371-371
Authors:
SU FM
HICKEY JJ
HOBSON LJ
FRITZBERG AR
RENO JM
Citation: Fm. Su et al., CHARACTERIZATION AND PREVENTION OF RADIOLYTIC DECOMPOSITION OF HIGH SPECIFIC ACTIVITY Y-90 DOTA-BIOTIN IN ANTIBODY PRETARGETING, The Journal of nuclear medicine, 37(5), 1996, pp. 726-726
Authors:
FRITZBERG AR
Citation: Ar. Fritzberg, TISSUE PERFUSION OF COPPER-62-PTSM - RELEVANCE OF STUDIES IN ANIMAL-MODELS AS PREDICTORS OF CLINICAL RADIOPHARMACEUTICAL PERFORMANCE, The Journal of nuclear medicine, 36(8), 1995, pp. 1456-1457
Authors:
FRITZBERG AR
BEAUMIER PL
BOTTINO BJ
RENO JM
Citation: Ar. Fritzberg et al., APPROACHES TO IMPROVED ANTIBODY-MEDIATED AND PEPTIDE-MEDIATED TARGETING FOR IMAGING AND THERAPY OF CANCER, Journal of controlled release, 28(1-3), 1994, pp. 167-173
Authors:
WEIDEN PL
BREITZ HB
SEILER CA
BJORN MJ
RATLIFF BA
MALLETT R
BEAUMIER PL
APPELBAUM JW
FRITZBERG AR
SALK D
Citation: Pl. Weiden et al., RHENIUM-186-LABELED CHIMERIC ANTIBODY NR-LU-13 - PHARMACOKINETICS, BIODISTRIBUTION AND IMMUNOGENICITY RELATIVE TO MURINE ANALOG NR-LU-10, The Journal of nuclear medicine, 34(12), 1993, pp. 2111-2119
Authors:
ANDERSON DC
NICHOLS E
MANGER R
WOODLE D
BARRY M
FRITZBERG AR
Citation: Dc. Anderson et al., TUMOR-CELL RETENTION OF ANTIBODY FAB FRAGMENTS IS ENHANCED BY AN ATTACHED HIV TAT PROTEIN-DERIVED PEPTIDE, Biochemical and biophysical research communications, 194(2), 1993, pp. 876-884
Risultati:
1-12
|